Ad
DEST - Destination Maternity Corporation Stock Trading
About | Destination Maternity Corporation (NASDAQ:DEST)
None
Quote | Destination Maternity Corporation (NASDAQ:DEST)
| Last: | $ |
|---|---|
| Change Percent: | 8.05% |
| Open: | $0.3703 |
| Close: | $0.3999 |
| High: | $0.418 |
| Low: | $0.33 |
| Volume: | 3,115,794 |
| Last Trade Date Time: | 10/15/2019 07:26:50 am |
News | Destination Maternity Corporation (NASDAQ:DEST)
-
(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than ...
-
(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Thomas Warner from Proactive after releasing the clinical-stage biotechnology company's full year results for 2022. Clark says that Destiny Pharma is focused on finding a partner for its lead asset, XF-73, ...
Message Board Posts | Destination Maternity Corporation (NASDAQ:DEST)
| Subject | By | Source | When |
|---|---|---|---|
| No posts yet. | |||
News, Short Squeeze, Breakout and More Instantly...
Destination Maternity Corporation Company Name:
DEST Stock Symbol:
NASDAQ Market:
Destination Maternity Corporation Website:
Ad
-
(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than ...
-
(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Thomas Warner from Proactive after releasing the clinical-stage biotechnology company's full year results for 2022. Clark says that Destiny Pharma is focused on finding a partner for its lead asset, XF-73, ...
-
(NewsDirect) Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief scientific officer Bill Love speaks to Proactive after results from a study into its C. Difficile treatment platform NTCD-M3 were published in the Microbiology Spectrum journal. Love explains what makes the platform so promis...